Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation

Critical Reviews in Oncology/Hematology

Volumn 88, Issue 2, 2013, Pages 272-283

  Giampieri, Riccardo ^a   Scartozzi, Mario ^a   Del Prete, Michela ^a   Maccaroni, Elena ^a   Bittoni, Alessandro ^a   Faloppi, Luca ^a   Bianconi, Maristella ^a   Cecchini, Luca ^a   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Anti EGFR; Biomarkers; Colorectal cancer; Resistance

Indexed keywords

AMPHIREGULIN; B RAF KINASE; BIOLOGICAL MARKER; CETUXIMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIREGULIN; FLUOROURACIL; FOLINIC ACID; GUANINE NUCLEOTIDE BINDING PROTEIN; IRINOTECAN; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; N RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN KINASE B; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

CANCER PROGNOSIS; CLINICAL PRACTICE; COLORECTAL CANCER; DRUG EFFICACY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; HUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTI-EGFR; BIOMARKERS; COLORECTAL CANCER; RESISTANCE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84885836502     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.05.008     Document Type: Review

References (65)

1. Harding J., Burtness B. Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody. Drugs Today (Barcelona) 2005, 41:107-127.
2. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New England Journal of Medicine 2004, 351:337-345.
3. Jonker D.J., O'Callaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. New England Journal of Medicine 2007, 357:2040-2048.
4. Chung K.Y., Shia J., Kemeny N.E., et al. Cetuximab shows activity in colorectal cancer patients with tumours that do not express the epidermal growth factor receptor by immunohistochemistry. Journal of Clinical Oncology 2005, 23(March (9)):1803-1810.
5. Hebbar M., Wacrenier A., Desauw C., et al. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 2006, 17(August (7)):855-857.
6. Downward J. Targeting RAS signalling pathways in cancer therapy. Nature Reviews Cancer 2003, 3:11-22.
7. Schubbert S., Shannon K., Bollag G. Hyperactive Ras in developmental disorders and cancer. Nature Reviews Cancer 2007, 7:295-308.
8. Bos J.L. Ras oncogenes in human cancer: a review. Cancer Research 1989, 49:4682-4689.
9. Amado R.G., Wolf M., Peeters M., et al. Wild-type Kras is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2008, 26(April (10)):1626-1634.
10. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Journal of Clinical Oncology 2007, 25(May (13)):1658-1664.
11. De Roock W., Jonker D.J., Di Nicolantonio F., et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with Cetuximab. Journal of the American Medical Association 2010, 304(16):1812-1820.
12. Tejpar S., Bokemeyer C., Celik I., et al. Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab. Presented as oral presentation at the gastrointestinal (colorectal) cancer session at the 2011 ASCO meeting. Abstract No. 3511 2011, [suppl.; abstr. 3511].
13. De Roock W., Claes B., Bernasconi D., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncology 2010, 11:753-762.
14. Loupakis F., Ruzzo A., Cremolini C., et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. British Journal of Cancer 2009, 101:715-721.
15. Oliner K.S., Peeters M., Siena S., et al. Evaluation of gene mutations beyond KRAS as predictive biomarkers of response to Panitumumab in a randomized, phase 3, monotherapy study of metastatic colorectal cancer (mCRC). Presented as poster in the gastrointestinal (colorectal) cancer session at the 2011 ASCO meeting. Abstract No. 3530 2011, [suppl.; abstr. 3530].
16. Maughan T.S., Adams R.A., Smith G.S., et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011, 377:2103-2114.
17. Di Nicolantonio F., Martini M., Molinari F., et al. Wild-Type BRAF is required for response to Panitumumab or Cetuximab in metastatic colorectal cancer. Journal of Clinical Oncology 2008, 26:5705-5712.
18. Laurent-Puig P., Cayre A., Manceau G., et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from Cetuximab therapy in wild-type KRAS metastatic colon cancer. Journal of Clinical Oncology 2009, 27:5924-5930.
19. Park J.H., Han S.W., Oh D.Y., et al. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. Cancer Chemotherapy and Pharmacology 2011, 68(October (4)):1045-1055. [Epub 22 February 2011].
20. Kohne C., Rougier P., Stroh C., et al. Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): a meta-analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. Gastrointestinal Cancers Symposium 2010, [Abstract No. 406].
21. Scartozzi M., Bearzi I., Mandolesi A., et al. Epidermal growth factor receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC Cancer 2009, 9(303).
22. Campanella C., Mottolese M., Cianciulli A., et al. Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab. Journal of Translational Medicine 2010, 8:36. April 16.
23. Yen L.C., Uen Y.H., Wu D.C., et al. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Annals of Surgery 2010, 251(February (2)):254-260.
24. Capuzzo F., Varella-Garcia M., Finocchiaro G., et al. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. British Journal of Cancer 2008, 99(1):83-89. July 8 [Epub 24 June 2008].
25. Personeni N., Fieuws S., Piessevaux H., et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clinical Cancer Research 2008, 14(18):5869-5876. September 15.
26. Li Y.H., Wang F., Shen L., et al. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to Cetuximab in KRAS wild-type metastatic colorectal cancer patients. Clinical Cancer Research 2011, 17:382-390.
27. Moroni M., Veronese S., Benvenuti S., et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncology 2005, 6(May (5)):279-286.
28. Sartore-Bianchi A., Moroni M., Veronese S., et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with Panitumumab. Journal of Clinical Oncology 2007, 25:3238-3245.
29. Zhang W., Gordon M., Press O.A., et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenetics and Genomics 2006, 16(July (7)):475-483.
30. Pander J., Gelderblom H., Antonini N.F., et al. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. European Journal of Cancer 2010, 46(July (10)):1829-1834. [Epub 24 April 2010].
31. Garm Spindler K.L., Pallisgaard N., Rasmussen A.A., et al. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Annals of Oncology 2009, 20(5):879-884. [Epub 29 January 2009].
32. Dahan L., Norguet E., Etienne-Grimaldi M.C., et al. Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC Cancer 2011, 11:496. November 25.
33. Lurje G., Nagashima F., Zhang W., et al. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clinical Cancer Research 2008, 14(23):7884-7895. December 1.
34. Loupakis F., Pollina L., Stasi I., et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. Journal of Clinical Oncology 2009, 27(16):2622-2629. June 1 [Epub 27 April 2009].
35. Li F.H., Shen L., Li Z.H., et al. Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer. World Journal of Gastroenterology 2010, 16(46):5881-5888. December 14.
36. Saridaki Z., Tzardi M., Papadaki C., et al. Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG expression and skin rash in 2nd line cetuximab-based therapy of colorectal cancer patients. PLoS ONE 2011, 6(1):e15980. January 20.
37. Tabernero J., Cervantes A., Rivera F., et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. Journal of Clinical Oncology 2010, 28(7):1181-1189. March 1 [Epub 25 January 2010]. 10.1200/JCO.2009.22.6043.
38. Tol J., Dijkstra J.R., Klomp M., et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. European Journal of Cancer 2010, 46(July (11)):1997-2009. [Epub 21 April 2010].
39. Negri F.V., Bozzetti C., Lagrasta C.A., et al. PTEN status in advanced colorectal cancer treated with cetuximab. British Journal of Cancer 2010, 102:162-164.
40. Prenen H., De Schutter J., Jacobs B., et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clinical Cancer Research 2009, 15:3184-3188.
41. Sartore-Bianchi A., Martini M., Molinari F., et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Research 2009, 69:1851-1857.
42. Jacobs B., De Roock W., Piessevaux H., et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. Journal of Clinical Oncology 2009, 27(30):5068-5074. October 20 [Epub 8 September 2009].
43. Khambata-Ford S., Garrett C.R., Meropol N.J., et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. Journal of Clinical Oncology 2013, 25:3230-3237.
44. Van Cutsem E., Kohne C.H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. New England Journal of Medicine 2009, 360:1408-1417.
45. Bokemeyer C., Bondarenko I., Hartmann J.T., et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Annals of Oncology 2011, 22(July (7)):1535-1546. [Epub 12 January 2011].
46. Tveit K., Guren T., Glimelius B., et al. Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: the NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group. Presented as poster in the gastrointestinal (colorectal) cancer session at the 2011 ASCO meeting. Abstract No. 365 2011, [suppl.; abstr. 365].
47. Douillard J.Y., Siena S., Cassidy J., et al. Randomized, phase III trial of Panitumumab with infusional Fluorouracil Leucovorin and Oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. Journal of Clinical Oncology 2010, 28(31):4697-4705. November 1 [Epub 4 October 2010].
48. Peeters M., Price T.J., Cervantes A., et al. Randomized phase III study of Panitumumab with Fluorouracil Leucovorin, and Irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2010, 28(31):4706-4713. November 1 [Epub 4 October 2010].
49. Scartozzi M., Mandolesi A., Giampieri R., et al. The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. Oncologist 2011, 16(1):53-60. [Epub 6 January 2011].
50. Barbara C., Martin V., Molinari F., et al. Use of HER2 gene amplification to identify patients with metastatic colorectal cancer resistant to anti-EGFR monoclonal antibodies. Presented as poster at the 2012 gastrointestinal cancers symposium, Abstract No. 474 2012, [suppl. 4; abstr. 474].
51. Finocchiaro G., Cappuzzo F., Jänne P.A., et al. EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer. Presented as poster at the 2007 ASCO annual meeting, Abstract No. 4021 2007, 4021. [June 20 Supplement].
52. Cappuzzo F., Varella-Garcia M., Finocchiaro G., et al. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. British Journal of Cancer 2008, 99(1):83-89. July 8 [Epub 24 June 2008].
53. Inno A., Di Salvatore M., Cenci T., et al. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?. Clinical Colorectal Cancer 2011, 10(December (4)):325-332. [Epub 11 May 2011].
54. Winder T., Zhang W., Yang D., et al. Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients. Clinical Cancer Research 2010, 16(22):5591-5602. November 15 [Epub 8 October 2010].
55. Scartozzi M., Mandolesi A., Giampieri R., et al. Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. International Journal of Cancer 2010, 127(8):1941-1947. October 15.
56. Akao Y., Nakagawa Y., Naoe T. Let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biological and Pharmaceutical Bulletin 2006, 29(May (5)):903-906.
57. Zhang W., Labonte M.J., Lenz H.J. KRAS let-7 LCS6 SNP predicts cetuximab efficacy in KRASwt metastatic colorectal cancer patients: does treatment combination partner matter?. Annals of Oncology 2011, 22(February (2)):484-485. [Epub 28 January 2011].
58. Graziano F., Canestrari E., Loupakis F., et al. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Pharmacogenomics Journal 2010 Oct, 10(5):458-464. [Epub 23 February 2010].
59. Liska D., Chen C.T., Bachleitner-Hofmann T., et al. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clinical Cancer Research 2011, 17(3):472-482. February 1 [Epub 22 November 2010].
60. Long I.S., Han K., Li M., et al. Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo. Molecular Cancer Research 2003, 1(March (5)):393-401.
61. Heindl S., Eggenstein E., Keller S., et al. Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines. Journal of Cancer Research and Clinical Oncology 2012, 138(5):843-858. May 2012.
62. Scartozzi M., Bearzi I., Mandolesi A., et al. Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. British Journal of Cancer 2011, 104(11):1786-1790. May 24 [Epub 10 May 2011].
63. Watkins D.J., Tabernero J., Schmoll H., et al. A randomized phase II/III study of the anti-IGF-1R antibody MK-0646 (dalotuzumab) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory metastatic colorectal cancer (mCRC) with wild-type (wt) KRAS status. Presented as oral presentation at the 2011 ASCO annual meeting, Abstract No. 3501 2011, [suppl.; abstr. 3501].
64. Montagut C., Dalmases A., Bellosillo B., et al. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nature Medicine 2012, 18(2):221-223. January 22. 10.1038/nm.2609.
65. Splinder K.L., Pallisgaard N., Lindebjerg J., et al. EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer. BMC Cancer 2011, 11:107. March 25. 10.1186/1471-2407-11-107.